BACKGROUND: The causes of post-Lyme disease symptoms are unclear. Herein, we investigated whether specific immune responses were correlated with such symptoms. METHODS: The levels of 23 cytokines and chemokines, representative of innate and adaptive immune responses, were assessed in sera from 86 antibiotic-treated European patients with erythema migrans, 45 with post-Lyme symptoms and 41 without symptoms, who were evaluated prior to treatment and 2, 6, and 12 months thereafter. RESULTS: At study entry, significant differences between groups were observed for the type 1 helper T cell (TH1)-associated chemokines CXCL9 and CXCL10, which were associated with negative Borrelia cultures, and the type 17 helper T cell (TH17)-associated cytokine interleukin 23 (IL-23), which was associated with positive cultures and the development of post-Lyme symptoms (P ≤ .02). Moreover, of the 41 patients with detectable IL-23 levels, 25 (61%) developed post-Lyme symptoms, and all 7 with IL-23 levels ≥ 230 ng/mL had such symptoms. Furthermore, antibody responses to the ECGF autoantigen were more common in patients with post-Lyme symptoms (P = .07) and were correlated directly with IL-23 levels (P = .02). Despite the presence of post-Lyme symptoms, all posttreatment culture results were negative, antiborrelial antibody responses declined, and there were no objective signs of disseminated disease, suggesting that spirochetal eradication had occurred with treatment in all patients. CONCLUSIONS: High TH1-associated responses correlated with more effective immune-mediated spirochetal killing, whereas high TH17-associated immune responses, often accompanied by autoantibodies, correlated with post-Lyme symptoms, providing a new paradigm for the study of postinfectious symptoms in a subset of patients with Lyme disease.
BACKGROUND: The causes of post-Lyme disease symptoms are unclear. Herein, we investigated whether specific immune responses were correlated with such symptoms. METHODS: The levels of 23 cytokines and chemokines, representative of innate and adaptive immune responses, were assessed in sera from 86 antibiotic-treated European patients with erythema migrans, 45 with post-Lyme symptoms and 41 without symptoms, who were evaluated prior to treatment and 2, 6, and 12 months thereafter. RESULTS: At study entry, significant differences between groups were observed for the type 1 helper T cell (TH1)-associated chemokines CXCL9 and CXCL10, which were associated with negative Borrelia cultures, and the type 17 helper T cell (TH17)-associated cytokine interleukin 23 (IL-23), which was associated with positive cultures and the development of post-Lyme symptoms (P ≤ .02). Moreover, of the 41 patients with detectable IL-23 levels, 25 (61%) developed post-Lyme symptoms, and all 7 with IL-23 levels ≥ 230 ng/mL had such symptoms. Furthermore, antibody responses to the ECGF autoantigen were more common in patients with post-Lyme symptoms (P = .07) and were correlated directly with IL-23 levels (P = .02). Despite the presence of post-Lyme symptoms, all posttreatment culture results were negative, antiborrelial antibody responses declined, and there were no objective signs of disseminated disease, suggesting that spirochetal eradication had occurred with treatment in all patients. CONCLUSIONS: High TH1-associated responses correlated with more effective immune-mediated spirochetal killing, whereas high TH17-associated immune responses, often accompanied by autoantibodies, correlated with post-Lyme symptoms, providing a new paradigm for the study of postinfectious symptoms in a subset of patients with Lyme disease.
Authors: M S Klempner; L T Hu; J Evans; C H Schmid; G M Johnson; R P Trevino; D Norton; L Levy; D Wall; J McCall; M Kosinski; A Weinstein Journal: N Engl J Med Date: 2001-07-12 Impact factor: 91.245
Authors: Gaia Codolo; Fleur Bossi; Paolo Durigutto; Chiara Della Bella; Fabio Fischetti; Amedeo Amedei; Francesco Tedesco; Sofia D'Elios; Marco Cimmino; Alessandra Micheletti; Marco A Cassatella; Mario M D'Elios; Marina de Bernard Journal: Arthritis Rheum Date: 2013-05
Authors: Maria O'Rourke; Andreas Traweger; Lara Lusa; Dasa Stupica; Vera Maraspin; P Noel Barrett; Franc Strle; Ian Livey Journal: PLoS One Date: 2013-05-16 Impact factor: 3.240
Authors: John N Aucott; Mark J Soloski; Alison W Rebman; Lauren A Crowder; Lauren J Lahey; Catriona A Wagner; William H Robinson; Kathleen T Bechtold Journal: Clin Vaccine Immunol Date: 2016-09-06
Authors: Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead Journal: Nat Rev Dis Primers Date: 2016-12-15 Impact factor: 52.329
Authors: Melanie Uhde; Alyssa Indart; Brian A Fallon; Gary P Wormser; Adriana R Marques; Suzanne D Vernon; Armin Alaedini Journal: Clin Infect Dis Date: 2018-09-28 Impact factor: 9.079
Authors: Daniel B Horton; Alysha J Taxter; Amy L Davidow; Brandt Groh; David D Sherry; Carlos D Rose Journal: J Rheumatol Date: 2019-03-01 Impact factor: 4.666
Authors: Kevin S Tang; Mark S Klempner; Gary P Wormser; Adriana R Marques; Armin Alaedini Journal: Clin Infect Dis Date: 2015-07-28 Impact factor: 9.079